As the Public Health Service (PHS) 340B program passes the 30-year mark, seminal events in the program’s history have shaped the landscape we see today. Far from being a bureaucratic regulation that all parties sleepily adopt, the 340B program has become a hot button for all those involved as well as those seeking to impact it from beyond the typical Covered Entity, Manufacturer and Government participants. With so many dollars at stake, attention – and tension – is riding high on actions by the existing stakeholders that have made a significant impact on the program in ways that were unimaginable a few short years ago. Where will the 340B program be 10 years from now? Will it survive as we know it?
The recent changes in the 340B program have a decided impact on and implications for patients, prescribers, payers, pharmacies, and the physical channel or flow of medications. We will explore each of those parties and end with specific calls to action for stakeholders in this critical program.
Contact Cynthia Keveney at Blue Fin Group for additional information. [email protected]
Click here to watch his video: https://bit.ly/3xbL1bL
Related Resources
To address the question of interchangeability and generic substitution, it’s natural to jump to oral, small molecule products which are self-administered. This market behaves rationally as branded products…
Learn More
Historically pharmaceutical manufacturer’s ability to generate demand with providers and patients was all that stood in the way of drugs realizing blockbuster status. During this large-market brand era the market…
Learn More
Blue Fin Group would like to share insights from an internal market research project assessing current and future payer management in oncology. You can watch the presentation from…
Learn More